For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Licensing revenue | 0 | 0 | 0 | - |
| Research and development | 12,826 | 16,415 | 11,278 | 8,612 |
| General and administrative | 2,991 | 4,651 | 3,393 | 3,627 |
| Total operating expenses | 15,817 | 21,066 | 14,671 | 12,239 |
| Loss from operations | -15,817 | -21,066 | -14,670 | -12,239 |
| Interest income | 1,558 | 1,185 | 1,762 | 1,758 |
| Net loss | -14,259 | -19,881 | -12,909 | -10,481 |
| Unrealized gain on marketable securities | 66 | 18 | -201 | 577 |
| Comprehensive loss | -14,193 | -19,863 | -13,110 | -9,904 |
| Net loss per share - basic and diluted (in dollars per share) | -0.08 | -0.14 | -0.09 | -0.08 |
| Us-gaap_weightedaveragenumberofsharesoutstandingbasic | 168,782,000 | 138,282,000 | -68,897,000 | 137,589,000 |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)